Vivendal 320 mg Filmdragerad tablett

Država: Švedska

Jezik: švedski

Izvor: Läkemedelsverket (Medical Products Agency)

Kupi sada

Uputa o lijeku Uputa o lijeku (PIL)
17-05-2018
Svojstava lijeka Svojstava lijeka (SPC)
22-04-2018

Aktivni sastojci:

valsartan

Dostupno od:

Sandoz A/S

ATC koda:

C09CA03

INN (International ime):

valsartan

Doziranje:

320 mg

Farmaceutski oblik:

Filmdragerad tablett

Sastav:

valsartan 320 mg Aktiv substans

Razred:

Apotek

Tip recepta:

Receptbelagt

Područje terapije:

Valsartan

Proizvod sažetak:

Förpacknings: Blister, 7 tabletter (plast/Al); Blister, 7 tabletter (Al); Blister, 10 tabletter (plast/Al); Blister, 14 tabletter (plast/Al); Blister, 15 tabletter (plast/Al); Blister, 20 tabletter (plast/Al); Blister, 28 tabletter (plast/Al); Blister, 30 tabletter (plast/Al); Blister, 50 tabletter (plast/Al); Blister, 50x1 tabletter (plast/Al); Blister, 56 tabletter (plast/Al); Blister, 60 tabletter (plast/Al); Blister, 84 tabletter (plast/Al); Blister, 90 tabletter (plast/Al); Blister, 98 tabletter (plast/Al); Blister, 100 tabletter (plast/Al); Blister, 280 tabletter (plast/Al); Blister, 10 tabletter (Al); Blister, 14 tabletter (Al); Blister, 15 tabletter (Al); Blister, 20 tabletter (Al); Blister, 28 tabletter (Al); Blister, 30 tabletter (Al); Blister, 50 tabletter (Al); Blister, 50x1 tabletter (Al); Blister, 56 tabletter (Al); Blister, 60 tabletter (Al); Blister, 84 tabletter (Al); Blister, 90 tabletter (Al); Blister, 98 tabletter (Al); Blister, 100 tabletter (Al); Blister, 280 tabletter (Al)

Status autorizacije:

Godkänd

Datum autorizacije:

2010-12-10

Uputa o lijeku

                                PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
VIVENDAL 40 MG FILM-COATED TABLETS
VIVENDAL 80 MG FILM-COATED TABLETS
VIVENDAL 160 MG FILM-COATED TABLETS
VIVENDAL 320 MG FILM-COATED TABLETS
valsartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Vivendal is and what it is used for
2.
What you need to know before you take Vivendal
3.
How to take Vivendal
4.
Possible side effects
5.
How to store Vivendal
6.
Contents of the pack and other information
1.
WHAT VIVENDAL IS AND WHAT IT IS USED FOR
Vivendal belongs to a class of medicines known as angiotensin II
receptor antagonist, which help to
control high blood pressure. Angiotensin II is a substance in the body
that causes vessels to tighten,
thus causing your blood pressure to increase. Vivendal works by
blocking the effect of angiotensin II.
As a result, blood vessels relax and blood pressure is lowered.
Vivendal 40 mg film-coated tablets
CAN BE USED FOR THREE DIFFERENT CONDITIONS:

TO TREAT HIGH BLOOD PRESSURE IN CHILDREN AND ADOLESCENTS 6 TO 18
YEARS OF AGE.
High blood
pressure increases the workload on the heart and arteries. If not
treated it can damage the blood
vessels of the brain, heart, and kidneys, and may result in a stroke,
heart failure, or kidney
failure. High blood pressure increases the risk of heart attacks.
Lowering your blood pressure to
normal reduces the risk of developing these disorders.

TO TREAT ADULT PATIENTS AFTER A RECENT HEART ATTACK
(myocardial infarction)
.
“Recent” here
means between 12 hours and 1
                                
                                Pročitajte cijeli dokument
                                
                            

Svojstava lijeka

                                MARKNADSFÖRS EJ FÖR NÄRVARANDE.
_Produktinformation_
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Uputa o lijeku Uputa o lijeku engleski 17-05-2018
Svojstava lijeka Svojstava lijeka engleski 17-05-2018
Izvješće o ocjeni javnog Izvješće o ocjeni javnog engleski 21-02-2013

Upozorenja za pretraživanje vezana za ovaj proizvod